{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:07Z","timestamp":1786998367932,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["150627"],"award-info":[{"award-number":["150627"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI116698"],"award-info":[{"award-number":["R01AI116698"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01HL064274"],"award-info":[{"award-number":["R01HL064274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017555","name":"Catalyst Biosciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ymthe.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:51:03Z","timestamp":1715032263000},"page":"2064-2079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques"],"prefix":"10.1016","volume":"32","author":[{"given":"Katja","family":"Pekrun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Gonzalez-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranyak","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice F.","family":"Tarantal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Blouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-2615","authenticated-orcid":false,"given":"Mark A.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.05.005_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2141.1998.00707.x","article-title":"Can haemophilic arthropathy be prevented?","volume":"101","author":"Ljung","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib2","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1097\/HS9.0000000000000540","article-title":"Hemophilia Gene Therapy: Approaching the First Licensed Product","volume":"5","author":"Batty","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.ymthe.2024.05.005_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2021000254","article-title":"Hemophilia gene therapy: ushering in a new treatment paradigm?","volume":"2021","author":"George","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2024.05.005_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/hum.2022.169","article-title":"Liver Gene Therapy","volume":"33","author":"Nathwani","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-Associated Virus Gene Therapy for Hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib6","doi-asserted-by":"crossref","first-page":"10766","DOI":"10.3390\/ijms241310766","article-title":"Gene Therapy Approaches for the Treatment of Hemophilia B","volume":"24","author":"Soroka","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.05.005_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/d41573-022-00199-8","article-title":"FDA approves first haemophilia B gene therapy","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.05.005_bib8","doi-asserted-by":"crossref","first-page":"e0240896","DOI":"10.1371\/journal.pone.0240896","article-title":"Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa","volume":"15","author":"Nichols","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.05.005_bib9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/hae.14315","article-title":"Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B","volume":"27","author":"Mahlangu","year":"2021","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2024.05.005_bib10","doi-asserted-by":"crossref","first-page":"e131610","DOI":"10.1172\/jci.insight.131610","article-title":"Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors","volume":"4","author":"Pekrun","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2024.05.005_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1158\/2159-8290.CD-21-0601","article-title":"Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts","volume":"12","author":"Helms","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.05.005_bib12","first-page":"76","article-title":"A high-throughput barcode screening identifies AAV-KP1 as a capsid that efficiently transduced pancreatic islets in hon-human primates following retrograde pancreatic duct injection","volume":"30","author":"Adachi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib13","article-title":"Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids","author":"Furusho","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2024.05.005_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.omtm.2023.08.004","article-title":"Selection of viral capsids and promoters affects the efficacy of rescue of Tmprss3-deficient cochlea","volume":"30","author":"Aaron","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.05.005_bib16","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib17","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib18","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib19","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41467-023-38106-3","article-title":"The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner","volume":"14","author":"Gonzalez-Sandoval","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.05.005_bib20","article-title":"Loss of transgene expression limits liver gene therapy in primates","author":"Greig","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2024.05.005_bib21","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/mt.2010.175","article-title":"Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy","volume":"18","author":"Hurlbut","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2021.04.010","article-title":"Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids","volume":"21","author":"Cabanes-Creus","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib24","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2020006005","article-title":"Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua","volume":"137","author":"Nair","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.005_bib25","doi-asserted-by":"crossref","first-page":"e1003294","DOI":"10.1371\/journal.pcbi.1003294","article-title":"Speed controls in translating secretory proteins in eukaryotes--an evolutionary perspective","volume":"10","author":"Mahlab","year":"2014","journal-title":"Plos Comput. Biol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.omtm.2022.12.014","article-title":"Characterization of the humanized FRG mouse model and development of an AAV-LK03 variant with improved liver lobular biodistribution","volume":"28","author":"Cabanes-Creus","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcp.21224","article-title":"DNA methylation: the nuts and bolts of repression","volume":"213","author":"Miranda","year":"2007","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tibs.2005.12.008","article-title":"Genomic DNA methylation: the mark and its mediators","volume":"31","author":"Klose","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ymthe.2024.05.005_bib29","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.0408436102","article-title":"Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression","volume":"102","author":"Song","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.05.005_bib30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/mthe.2000.0075","article-title":"Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in\u00a0vivo but not in\u00a0vitro","volume":"1","author":"Miao","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1073\/pnas.85.3.836","article-title":"Introns increase transcriptional efficiency in transgenic mice","volume":"85","author":"Brinster","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.05.005_bib32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1073\/pnas.88.2.478","article-title":"Heterologous introns can enhance expression of transgenes in mice","volume":"88","author":"Palmiter","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.05.005_bib33","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1073\/pnas.92.17.7724","article-title":"Rat growth hormone gene introns stimulate nucleosome alignment in\u00a0vitro and in transgenic mice","volume":"92","author":"Liu","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.05.005_bib34","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib35","doi-asserted-by":"crossref","first-page":"672449","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.005_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced Factor IX Activity following Administration of AAV5-R338L \"Padua\" Factor IX versus AAV5 WT Human Factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2021.08.001","article-title":"Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette","volume":"23","author":"Kumar","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib41","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/blood-2019-124734","article-title":"Evaluation of the Human Factor IX Gene Therapy Vector TAK-748 in Hemophilia: Results from Non-Clinical Studies in Factor IX Knockout Mice and Rhesus Monkeys","volume":"134","author":"Weiller","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.005_bib42","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib44","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.005_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fmicb.2011.00244","article-title":"Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B","volume":"2","author":"Nayak","year":"2011","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib47","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1182\/bloodadvances.2021006359","article-title":"Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice","volume":"6","author":"Lundgren","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.05.005_bib48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In\u00a0Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib49","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/jcm10112471","article-title":"Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia","volume":"10","author":"Monahan","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib51","doi-asserted-by":"crossref","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib52","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib53","article-title":"Direct bisulfite sequencing for examination of DNA methylation with gene and nucleotide resolution from brain tissues","volume":"7","author":"Parrish","year":"2012","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.ymthe.2024.05.005_bib54","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2007.01.015","article-title":"The role of chromatin during transcription","volume":"128","author":"Li","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.05.005_bib55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrg2540","article-title":"Linking DNA methylation and histone modification: patterns and paradigms","volume":"10","author":"Cedar","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2024.05.005_bib56","doi-asserted-by":"crossref","first-page":"e20881","DOI":"10.1371\/journal.pone.0020881","article-title":"Adeno-associated viral vector-mediated transgene expression is independent of DNA methylation in primate liver and skeletal muscle","volume":"6","author":"Leger","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.05.005_bib57","doi-asserted-by":"crossref","first-page":"e0203921","DOI":"10.1128\/jvi.02039-21","article-title":"Epigenetic Silencing of Recombinant Adeno-associated Virus Genomes by NP220 and the HUSH Complex","volume":"96","author":"Das","year":"2022","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.05.005_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omtm.2021.11.005","article-title":"Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A","volume":"24","author":"Elkouby","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.005_bib59","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib61","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib62","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib63","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib64","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib65","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.05.005_bib66","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.05.005_bib67","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.005_bib68","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.05.005_bib69","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/mt.2012.65","article-title":"The extragenic spacer length between the 5' and 3' ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors","volume":"20","author":"Lu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib70","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.gt.3302231","article-title":"Silencing of episomal transgene expression by plasmid bacterial DNA elements in\u00a0vivo","volume":"11","author":"Chen","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.005_bib71","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.005_bib72","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.05.005_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in\u00a0vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2024.05.005_bib74","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","article-title":"MethPrimer: designing primers for methylation PCRs","volume":"18","author":"Li","year":"2002","journal-title":"Bioinformatics"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:40:20Z","timestamp":1762548020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162400306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S152500162400306X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}